Newsletter Tool

To view this email as a web page, click here

Today's Rundown

FDA leaders, facing doubts over the agency's independence, pledge to 'follow the science' amid pandemic
With surge in virtual care, Teladoc, Livongo execs saw the chance to "accelerate" with massive deal
Verily nets FDA authorization for pooled COVID-19 testing
Celltrion passes early safety trial for anti-COVID-19 antibody as key tests await
UnitedHealth Group CEO: Pandemic pushes providers to take more serious look at shift to value
Healthcare roundup: CommonSpirit Health opens new lab for COVID-19 testing
Biopharma roundup: Verily grabs go-ahead to run COVID-19 pooled testing; Celltrion's monoclonal antibody hits the mark in early safety trial
During the pandemic, data sharing has proven to be a challenge. Here's how Healthfirst's HIE helped NYC hospitals
Sarepta cites 'overburdened' FDA as factor in DMD gene therapy delay
Flagship Pioneering debuts new startup using AI to design disease-fighting proteins

Featured Story

FDA leaders, facing doubts over the agency's independence, pledge to 'follow the science' amid pandemic

By Eric Sagonowsky

After a series of controversial decisions by the FDA so far in the COVID-19 pandemic, questions have circled over whether politics are entering the agency's decision-making process. Aware of questions and criticisms surrounding the agency, key FDA leaders are pledging to always put science first.

With surge in virtual care, Teladoc, Livongo execs saw the chance to "accelerate" with massive deal

By Heather Landi

Teladoc is betting big on the continued growth of virtual care with its $18.5 billion deal to buy Livongo. Executives from both companies say the timing for the deal, even in the middle of a pandemic, was exactly right.

Verily nets FDA authorization for pooled COVID-19 testing

By Conor Hale

Verily has received a go-ahead from the FDA to begin pooled testing for COVID-19 to help scale up its screening efforts.

Celltrion passes early safety trial for anti-COVID-19 antibody as key tests await

By Ben Adams

Vaccines get all the headlines, but the use of antibodies to both treat and prevent SARS-CoV-02 infection is an equally major part of the COVID-19 arsenal.

UnitedHealth Group CEO: Pandemic pushes providers to take more serious look at shift to value

By Robert King

COVID-19 is causing more providers to take a look at making the switch to value-based care as their fee-for-service volumes plummet, key executives say.

Healthcare roundup: CommonSpirit Health opens new lab for COVID-19 testing

By Healthcare Staff

Follow along with the latest COVID-19 news straight from the Fierce Healthcare team.

Biopharma roundup: Verily grabs go-ahead to run COVID-19 pooled testing; Celltrion's monoclonal antibody hits the mark in early safety trial

By Eric Sagonowsky, Angus Liu, Kyle Blankenship, Conor Hale, Fraiser Kansteiner

Verily won a green light to run pooled testing for COVID-19. Celltrion published promising safety data on its anti-COVID-19 antibody. Chinese drugmakers have already injected thousands with experimental vaccines. The UN cautioned against countries hoarding vaccine supplies. Plus, President Trump acknowledged downplaying the pandemic threat in a leaked interview clip.

During the pandemic, data sharing has proven to be a challenge. Here's how Healthfirst's HIE helped NYC hospitals

By Heather Landi

In New York City, which was hard-hit by the pandemic in April and May, a data-sharing platform proved to be a lifeline for health systems including NYU Langone Health, Mount Sinai and Northwell Health. The health information exchange ties together critical patient information from insurer Healthfirst and 15 local hospitals.

Sarepta cites 'overburdened' FDA as factor in DMD gene therapy delay

By Nick Paul Taylor

Burdens placed on the FDA by COVID-19 and the rapid proliferation of cell and gene therapies are a factor in the recent setback to Sarepta Therapeutics’ Duchenne muscular dystrophy (DMD) prospect, according to CEO Douglas Ingram.

Flagship Pioneering debuts new startup using AI to design disease-fighting proteins